Rubraca Receives Conditional FDA Approval for metastatic CRPC Patients with BRCA Mutations

The U.S. Food and Drug Administration (FDA) has granted conditional approval to Rubraca (rucaparib) for treating patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA mutations who have previously received an androgen receptor inhibitor and taxane-based chemotherapy. The agency’s decision was made under an accelerated approval process after previously granting the therapy breakthrough therapy designation and priority review status for the same indication. It was based on promising response rates and duration of responses seen…

You must be logged in to read/download the full post.